Clinical Trials Directory

Trials / Unknown

UnknownNCT02678481

MR-targeted vs. Random TRUS-guided Prostate Biopsy

MR-targeted vs. Random TRUS-guided Prostate Biopsy in Patients With High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Fondazione del Piemonte per l'Oncologia · Academic / Other
Sex
Male
Age
50 Years – 80 Years
Healthy volunteers
Not accepted

Summary

To compare prostate cancer (PCa) detection rate of magnetic resonance (MR)-targeted biopsy and transrectal ultrasound (TRUS)-guided biopsy in patients with high PSA values and at least one previous negative prostate biopsy. Subjects will be submitted to a multiparametric MR scan of the prostate and subsequently patients with a suspicious MR for PCa presence will be randomized (1:1) into the two study arms.

Detailed description

In men with previously negative prostate biopsy and persistent elevated PSA value, it is unclear which biopsy strategy offers the highest detection rate for significant PCa. The hypothesis of this study is that MR-targeted biopsy improves the detection rates of significant prostate cancers compared with systematic TRUS-guided prostate biopsy. Men with at least one previously negative TRUS-guided biopsy and persistently elevated PSA values (\> 4 ng/ml) will be submitted to a multiparametric MR imaging examination of the prostate. Subsequently, participants with suspected regions at MR imaging will be randomized (1:1) into the two study arms. In study arm A patients will be submitted to MR-targeted in-bore prostate biopsy based on the multiparametric MR imaging findings. In study arm B patients will be submitted to systematic TRUS-guided prostate biopsy with saturation scheme.

Conditions

Interventions

TypeNameDescription
DEVICEMR-guided in-bore prostate biopsy2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
DEVICETRUS-guided prostate biopsy24-28 systematic biopsy core (saturation scheme)

Timeline

Start date
2014-11-01
Primary completion
2016-08-01
Completion
2016-12-01
First posted
2016-02-09
Last updated
2016-08-22

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT02678481. Inclusion in this directory is not an endorsement.